Reuters |
AbbVie's positive eczema study drags down Regeneron's shares
Reuters (Reuters) – AbbVie Inc said on Thursday its experimental drug to treat adults with moderate-to-severe eczema met the main goal in a mid-stage study, dragging down shares of rival U.S. biotech firm Regeneron Pharmaceuticals Inc. Eczema, also known as … AbbVie Inc (ABBV) Stock Surges on Positive Eczema Study AbbVie shares rally on positive eczema study, competitor Regeneron drops How AbbVie Could Chip Away At Regeneron's Potential Blockbuster |
